January 14, 2020
Kaken Pharmaceutical has filed a new drug application (NDA) in Japan for its primary axillary hyperhidrosis treatment BBI-4000 (sofpironium bromide), it said on January 10. The compound was licensed from US biopharma Brickell Biotech in March 2015. It belongs to...read more